ACB A Randomized Study of 2.5ug/kg/Day vs. 5ug/kg/Day Dose of G-CSF After High Dose Chemotherapy Followed by Autologous Peripheral Blood Stem Cell/Marrow Transplant Recipients FILE#17159

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00168168

Enrollment

Registered

2005-09-15

Start date

2003-07-31

Completion date

2007-02-28

Last updated

2010-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral Stem Cell/Marrow Transplant

Keywords

G-CSF, Filgrastim, Engraftment time, Autologus transplant

Brief summary

Evaluate recovery time on 2.5 mg/Kg/day dose of G-CSF versus 5 mg/Kg/day dose.

Interventions

DRUGG-CSF/Filgrastim

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* over age 18 * autologous stem cell/marrow transplant candidate in MM, lymphoma, AMG and testicular

Exclusion criteria

* age below 18 years * sensitive to G-CSF

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026